{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:02:13Z","timestamp":1788447733568,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2 017ZX10202202-002-004"],"award-info":[{"award-number":["2 017ZX10202202-002-004"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2 017ZX10202203-008-005"],"award-info":[{"award-number":["2 017ZX10202203-008-005"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijid.2021.03.023","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T13:19:17Z","timestamp":1616073557000},"page":"626-631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0556-8722","authenticated-orcid":false,"given":"Jin","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rili","family":"M ise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.03.023_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1423-0127-20-61","article-title":"Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate-induced mitochondrial damage and increased oxido-nitrosative stress in the kidney","volume":"20","author":"Abraham","year":"2013","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ijid.2021.03.023_bib0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2021.03.023_bib0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hep.27837","article-title":"Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus","volume":"62","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2021.03.023_bib0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/QAD.0b013e32835c208b","article-title":"The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women","volume":"27","author":"Colbers","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2021.03.023_bib0030","doi-asserted-by":"crossref","first-page":"e01686","DOI":"10.1128\/AAC.01686-18","article-title":"Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus","volume":"62","author":"Cressey","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.03.023_bib0035","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1128\/AAC.00544-11","article-title":"Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants","volume":"55","author":"Flynn","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.03.023_bib0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2016.08.008","article-title":"Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)\/TDF in lamivudine resistant hepatitis B: a 5-year randomised study","volume":"66","author":"Fung","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0045","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/MEG.0000000000001662","article-title":"The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B","volume":"32","author":"Gao","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2014.04.038","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus","volume":"61","author":"Greenup","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jhep.2011.02.032","article-title":"A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection","volume":"55","author":"Han","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.10.007","article-title":"Management algorithm for interrupting mother-to-child transmission of hepatitis B virus","volume":"17","author":"Hou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0065","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3748\/wjg.v25.i23.2961","article-title":"Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: systematic review with meta-analysis","volume":"25","author":"Lee","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.03.023_bib0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jvh.12066","article-title":"Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy","volume":"20","author":"Liu","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijid.2021.03.023_bib0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2016.12.012","article-title":"Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro","volume":"139","author":"Liu","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijid.2021.03.023_bib0080","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ijid.2021.03.023_bib0085","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.dld.2019.06.009","article-title":"Fanconi syndrome due to tenofovir disoproxil fumarate (TDF) after liver transplantation","volume":"51","author":"Llach","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ijid.2021.03.023_bib0090","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.03.023_bib0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/jvh.12794","article-title":"Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis","volume":"24","author":"Pan","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijid.2021.03.023_bib0100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jbt.21560","article-title":"Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate nephrotoxicity","volume":"28","author":"Ramamoorthy","year":"2014","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5604\/16652681.1231580","article-title":"Lamivudine, entecavir, or tenofovir treatment of hepatitis B infection: effects on calcium, phosphate, FGF23 and indicators of bone metabolism","volume":"16","author":"Saeedi","year":"2017","journal-title":"Ann Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2021.03.023_bib0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jvh.12785","article-title":"Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: long-term follow-up","volume":"24","author":"Shang","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijid.2021.03.023_bib0120","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2021.03.023_bib0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni1317","article-title":"Mother\u2019s little helpers: mechanisms of maternal\u2013fetal tolerance","volume":"7","author":"Trowsdale","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.05.035","article-title":"Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience","volume":"22","author":"Tsai","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2021.03.023_bib0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/vim.2016.0007","article-title":"Low ratio of Treg to Th17 cells after 36 weeks of telbivudine therapy predict HBeAg seroconversion","volume":"29","author":"Wang","year":"2016","journal-title":"Viral Immunol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0140","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jhep.2020.01.021","article-title":"Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate","volume":"71","author":"Wen","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0145","series-title":"Global hepatitis report, 2017","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.ijid.2021.03.023_bib0150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/MEG.0000000000001345","article-title":"Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study","volume":"31","author":"Wu","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2021.03.023_bib0155","doi-asserted-by":"crossref","first-page":"f4503","DOI":"10.1136\/bmj.f4503","article-title":"The next step in controlling HBV in China","volume":"347","author":"Xu","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2021.03.023_bib0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1743-422X-7-211","article-title":"Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review","volume":"7","author":"Zhao","year":"2010","journal-title":"Virol J"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221002411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221002411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:11:10Z","timestamp":1778519470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221002411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"alternative-id":["S1201971221002411"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.03.023","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}